This special session will explore the transformative impact of gene therapy for sickle cell disease. The session includes the firsthand perspective of Ms. Victoria Gray.
Ms. Gray is the first patient in the United States to undergo revolutionary CRISPR treatment for Sickle Cell Disease. After decades of pain and struggle, Ms. Gray's CRISPR procedure has not only modified her affected cells, she has not needed any transfusions and has not experienced any pain attacks.
In addition to Ms. Gray's story, the session will provide a brief update on gene therapy and treatment of Sickle Cell Disease. The session faculty will also discuss the ethical considerations surrounding patient selection, cost of gene therapy, and policies currently in place/needed for ensuring equitable access.
The session is meant to be an introduction to the implications the gene therapy revolution may have on individuals, health care organizations, and the broader landscape of health care delivery in the United States.
Watch our recent 5-Minute Check In about Sickle Cell Disease: https://youtu.be/clUcAR_tPbw?si=cW6Df4i6_S0bnbOa